Viral Glomerulopathy
Background: The association between viral infections and glomerular diseases, commonly known as “viral glomerulopathies,” has been described in various clinical scenarios for decades. Despite advancements in diagnostic tools, it remains challenging to establish a causative link fully. Summary: Data...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-08-01
|
| Series: | Glomerular Diseases |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/531434 |
| _version_ | 1797690741570404352 |
|---|---|
| author | Margaret Deoliveira Hridyesh Sikri Samuel Mon-Wei Yu John Cijiang He |
| author_facet | Margaret Deoliveira Hridyesh Sikri Samuel Mon-Wei Yu John Cijiang He |
| author_sort | Margaret Deoliveira |
| collection | DOAJ |
| description | Background: The association between viral infections and glomerular diseases, commonly known as “viral glomerulopathies,” has been described in various clinical scenarios for decades. Despite advancements in diagnostic tools, it remains challenging to establish a causative link fully. Summary: Data from mouse models have substantiated clinical observations and implicate direct viral infection in the pathogenesis of viral glomerulopathy, particularly in human immunodeficiency virus-associated nephropathy. In addition to the traditional concept of direct viral effects on kidneys, other factors such as APOL1 risk alleles can further modify the clinical outcomes or presentations of different viral glomerulopathies. Newly developed antiviral drugs are now applicable to a wider range of patients with lower kidney function and fewer side effects. Key Message: Efforts focusing on vaccines and antiviral treatments have significantly reduced the incidence of viral glomerulopathies. However, the most recent pandemic caused by severe acute respiratory syndrome coronavirus 2 infection complicated by COVID-associated nephropathy illustrates our susceptibility to novel viruses. Ongoing research is pivotal to deciphering the mechanisms behind viral glomerulopathies and discovering therapeutics in a collaborative approach. |
| first_indexed | 2024-03-12T02:03:29Z |
| format | Article |
| id | doaj.art-b00a23bd6d2847689a0a59e4436c0cab |
| institution | Directory Open Access Journal |
| issn | 2673-3633 |
| language | English |
| last_indexed | 2024-03-12T02:03:29Z |
| publishDate | 2023-08-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Glomerular Diseases |
| spelling | doaj.art-b00a23bd6d2847689a0a59e4436c0cab2023-09-07T07:56:39ZengKarger PublishersGlomerular Diseases2673-36332023-08-013114815410.1159/000531434531434Viral GlomerulopathyMargaret Deoliveira0Hridyesh Sikri1Samuel Mon-Wei Yu2John Cijiang He3Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USADivision of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USADivision of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USADivision of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USABackground: The association between viral infections and glomerular diseases, commonly known as “viral glomerulopathies,” has been described in various clinical scenarios for decades. Despite advancements in diagnostic tools, it remains challenging to establish a causative link fully. Summary: Data from mouse models have substantiated clinical observations and implicate direct viral infection in the pathogenesis of viral glomerulopathy, particularly in human immunodeficiency virus-associated nephropathy. In addition to the traditional concept of direct viral effects on kidneys, other factors such as APOL1 risk alleles can further modify the clinical outcomes or presentations of different viral glomerulopathies. Newly developed antiviral drugs are now applicable to a wider range of patients with lower kidney function and fewer side effects. Key Message: Efforts focusing on vaccines and antiviral treatments have significantly reduced the incidence of viral glomerulopathies. However, the most recent pandemic caused by severe acute respiratory syndrome coronavirus 2 infection complicated by COVID-associated nephropathy illustrates our susceptibility to novel viruses. Ongoing research is pivotal to deciphering the mechanisms behind viral glomerulopathies and discovering therapeutics in a collaborative approach.https://beta.karger.com/Article/FullText/531434viral glomerulopathycovid-19human immunodeficiency virushepatitis b virushepatitis c virus |
| spellingShingle | Margaret Deoliveira Hridyesh Sikri Samuel Mon-Wei Yu John Cijiang He Viral Glomerulopathy Glomerular Diseases viral glomerulopathy covid-19 human immunodeficiency virus hepatitis b virus hepatitis c virus |
| title | Viral Glomerulopathy |
| title_full | Viral Glomerulopathy |
| title_fullStr | Viral Glomerulopathy |
| title_full_unstemmed | Viral Glomerulopathy |
| title_short | Viral Glomerulopathy |
| title_sort | viral glomerulopathy |
| topic | viral glomerulopathy covid-19 human immunodeficiency virus hepatitis b virus hepatitis c virus |
| url | https://beta.karger.com/Article/FullText/531434 |
| work_keys_str_mv | AT margaretdeoliveira viralglomerulopathy AT hridyeshsikri viralglomerulopathy AT samuelmonweiyu viralglomerulopathy AT johncijianghe viralglomerulopathy |